Skip to main content
Kuros Biosciences Ltd. logo

Kuros Biosciences Ltd. — Investor Relations & Filings

Ticker · KURN ISIN · CH0325814116 LEI · 5299006U5POB2AVTT709 SW Manufacturing
Open in API
Filings indexed 207 across all filing types
Latest filing 2018-05-14 Regulatory Filings
Country CH Switzerland
Listing SW KURN

About Kuros Biosciences Ltd.

https://kurosbio.com/

Kuros Biosciences is a life sciences company that discovers, develops, and delivers innovative biologic technologies focused on tissue repair and bone regeneration. The company's mission is to address unmet clinical needs for safer, faster, and more predictable bone healing. Its primary commercial product is MagnetOs, an advanced bone graft designed to enhance bone formation. The efficacy of MagnetOs is supported by a comprehensive global research program, "Project Fusion," which includes scientific, pre-clinical, and Level I human clinical studies. Kuros Biosciences serves surgeons and patients across multiple medical fields, including spine, extremities, trauma, and oncology, leveraging deep scientific expertise and collaboration with leading clinical experts.

Recent filings

Filing Released Lang Actions
Kuros Biosciences AG (KURN-CH): Differentiated orthobiologics for spinal fusion:
Regulatory Filings Classification · 99% confidence The document is an email or announcement from 'goetzpartners securities Limited' dated May 14, 2018, providing an equity research report on Kuros Biosciences AG. It contains a recommendation ('OUTPERFORM'), target price, key takeaways, and detailed analysis of the company's products and market. Crucially, the text states: 'GPSL Equity Research publications are available on the following aggregators...' and provides a hyperlink to the full PDF version, concluding with 'Dissemination of a CORPORATE NEWS, transmitted by EQS Group.' This structure—an announcement distributing external research content, often with a link to the full document—fits the definition of a Report Publication Announcement (RPA) rather than the full research report itself (which would likely be classified as Investor Presentation (IP) if it were the primary document). Since the document is primarily announcing the availability and summarizing the content of a research report, RPA is the most appropriate classification based on the 'MENU VS MEAL' rule.
2018-05-14 English
Kuros appoints Philippe Saudan as Chief Development Officer
Board/Management Information Classification · 100% confidence The document is explicitly labeled as an "Ad-hoc" announcement released on August 10, 2016. The content details the appointment of a new Chief Development Officer (Philippe Saudan) and mentions 'Change of Personnel' as a key word. This type of announcement, concerning changes in senior management or the board of directors, directly corresponds to the definition for Board/Management Information (MANG). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific personnel change.
2016-08-10 English
Kuros Biosciences AG: valuationLAB Initiates Research Coverage on Kuros
Regulatory Filings Classification · 100% confidence The document is an 'Ad-hoc' announcement from Kuros Biosciences AG dated June 28, 2016. The core content is the announcement that an independent research boutique, valuationLAB, has initiated research coverage on Kuros and provided a valuation report. The document summarizes key findings from this external research report (NPV estimate, pipeline details, upcoming milestones) and explicitly states that the full analyst research report is available elsewhere ('The full analyst research report is available from www.valuationlab.com and Kuros’ website'). Since this document is an announcement *about* the publication of a research report, rather than the report itself (which would likely be classified as Investor Presentation (IP) or potentially Financial Supplement Data (XLSX) if it were the raw data), it fits best under the category for announcements regarding the release of company reports or related materials. Given the options, this is a general regulatory announcement concerning external research coverage, which often falls under Regulatory Filings (RNS) if no other specific category fits perfectly. However, since it is announcing the availability of a research report, it is closely related to Investor Presentation (IP) or a general announcement. Since it is not a formal company report (like 10-K or IR) but an announcement of third-party research, RNS is the most appropriate general regulatory fallback for this type of news release that doesn't fit the specific definitions like DIV, DIRS, or ER.
2016-06-28 English
First Trading Day of New Kuros Share after Reverse Split
Share Issue/Capital Change Classification · 99% confidence The document is an 'Ad-hoc' announcement dated June 23, 2016, detailing the 'First Trading Day of New Kuros Share after Reverse Split'. A reverse split is a change in the capital structure of the company, where 100 existing shares are exchanged for 1 new share. This action directly relates to the company's share count and capital structure. Reviewing the definitions, 'Share Issue/Capital Change (SHA)' is the most appropriate category, as it covers changes to the capital structure, including stock splits/reverse splits. Although the reverse split was approved at the AGM, the document focuses on the execution and result of the capital change, not the AGM materials themselves (AGM-R) or the voting results (DVA). It is a specific corporate action announcement.
2016-06-23 English
Kuros Bioscience's Shareholders Approve All Resolutions
AGM Information Classification · 99% confidence The document is an 'Ad-hoc' announcement dated June 16, 2016, with the title 'Kuros Bioscience’s Shareholders Approve All Resolutions'. The key phrase in the header is 'Key word(s): AGM/EGM'. The text explicitly discusses the outcomes of the 'Annual Shareholders’ Meeting 2016', including the approval of resolutions like a reverse stock split and the election of a new board member. This content directly relates to the proceedings and outcomes of the Annual General Meeting. Therefore, the appropriate classification is AGM Information (AGM-R). The document length is short (4183 chars) and it is an announcement summarizing the meeting results, not the full presentation materials, but AGM-R is the most specific category for AGM outcomes.
2016-06-16 English
Kuros Biosciences Invites to the Annual Shareholders' Meeting 2016
AGM Information Classification · 99% confidence The document explicitly states in the title and body that it is an invitation to the 'Annual Shareholders’ Meeting 2016' (AGM). It discusses the date of the meeting and proposals to be voted on, such as a reverse stock split and board member elections. This directly corresponds to the definition of AGM Information (AGM-R). Although it mentions the formal invitation will be sent out later, the content itself is the announcement and details pertaining to the AGM.
2016-05-26 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.